Scarica l'app Stockscreener
142.44
0.84%
1.19
Precedente Chiudi:
$141.25
Aprire:
$141.33
Volume 24 ore:
1.02M
Relative Volume:
0.68
Capitalizzazione di mercato:
$14.48B
Reddito:
$3.10B
Utile/perdita netta:
$668.60M
Rapporto P/E:
21.90
EPS:
6.5044
Flusso di cassa netto:
$831.30M
1 W Prestazione:
-0.52%
1M Prestazione:
-8.19%
6M Prestazione:
+8.20%
1 anno Prestazione:
+2.87%
Intervallo 1D:
$140.02
$143.55
Intervallo di 1 settimana:
$140.02
$145.88
Portata 52W:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
142.44 | 14.48B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
18.73 | 59.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.10 | 47.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.32 | 40.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.81 | 30.91B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.16 | 23.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-06 | Ripresa | Guggenheim | Buy |
| 2026-06-02 | Ripresa | Goldman | Buy |
| 2026-05-22 | Iniziato | Bernstein | Outperform |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. - Stock Titan
Neurocrine Biosciences (NBIX) After New VYKAT XR Data Why The Undervalued Narrative Persists - Simply Wall Street
Neurocrine Biosciences stock fell 1.4 percent before research event - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock - ChartMill
Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high - AD HOC NEWS
Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst - Moomoo
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board - Endpoints News
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Australia
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference - PR Newswire
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
Neurocrine Biosciences selects Ruder Finn as communications AOR - Medical Marketing and Media
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance UK
UBS cuts Neurocrine Biosciences stock price target to $214 on competition - Investing.com
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
EBITDA margin % of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return - Simply Wall Street
Neurocrine Biosciences names Eiry Roberts as chief medical officer - Investing.com
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - marketscreener.com
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - Yahoo Finance
Neurocrine names Eiry Roberts chief medical officer - Stock Titan
Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes - marketscreener.com
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - PR Newswire
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - Nasdaq
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - easternprogress.com
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - simplywall.st
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - tradingview.com
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Nigeria
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Canada
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com India
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com UK
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DAVID WARREN BOYER | Officer |
Sep 14 '26 |
Proposed Sale |
156.22 |
4,714 |
736,421 |
0 |
| MATTHEW C ABERNETHY | Officer |
Sep 14 '26 |
Proposed Sale |
156.22 |
2,311 |
361,024 |
0 |
| ABERNETHY MATT | Chief Financial Officer |
Sep 14 '26 |
Sale |
157.20 |
2,311 |
363,285 |
42,808 |
| ERIC BENEVICH | Officer |
Sep 09 '26 |
Proposed Sale |
155.13 |
2,154 |
334,150 |
0 |
| BENEVICH ERIC | Chief Commercial Officer |
Sep 09 '26 |
Sale |
154.61 |
2,154 |
333,030 |
64,408 |
| BENEVICH ERIC | Chief Commercial Officer |
Sep 09 '26 |
Option Exercise |
43.24 |
3,194 |
138,109 |
66,562 |
| Norwalk Leslie V | Director |
Jul 29 '26 |
Option Exercise |
139.43 |
842 |
117,400 |
2,430 |
| Norwalk Leslie V | Director |
Jul 28 '26 |
Sale |
182.01 |
1,250 |
227,508 |
1,588 |
| INGRID DELAET | Officer |
Jul 10 '26 |
Proposed Sale |
180.55 |
4,367 |
788,462 |
0 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Option Exercise |
106.02 |
4,367 |
462,989 |
20,592 |
1.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):